Insulet Corp. (NASDAQ:PODD) shares are down during Friday’s premarket session following the company’s announcement of a voluntary Medical Device Correction for certain lots of Omnipod 5 Pods.
Manufacturing Defect
Insulet identified a manufacturing issue affecting specific lots of Omnipod 5 Pods, which may have a small tear in the internal tubing that delivers insulin.
This could lead to under-delivery of insulin, potentially resulting in high blood glucose levels and serious medical conditions, including diabetic ketoacidosis (DKA); the company has received 18 reports of serious adverse events related to this issue.
Diabetic ketoacidosis is a life-threatening, critical metabolic emergency, primarily in type 1 diabetes, where insufficient insulin causes the body to burn fat for fuel, producing high levels of blood acids (ketones).
The affected Pods represent approximately 1.5% of annual production globally, and Insulet has assured that all other Omnipod products remain safe for use.
Insulet on Thursday noted that the issue does not affect continuous glucose monitoring (CGM) systems or CGM readings.
Insulet Technical Analysis
The stock is currently trading 8.63% below its 20-day simple moving average (SMA) and 14.45% below its 100-day SMA, indicating a bearish trend in the short to medium term. Shares have decreased 3.51% over the past 12 months and are currently positioned closer to their 52-week lows than highs.
The RSI is at 37.55, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD is at -6.1188, above its signal line at -6.4232, indicating a bullish crossover that may suggest potential upward momentum.
The combination of neutral RSI and bullish MACD suggests mixed momentum, indicating that while there may be some buying interest, the stock is still facing significant selling pressure.
- Key Resistance: $244.00
- Key Support: $220.00
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $356.64. Recent analyst moves include:
- Citigroup: Buy (Lowers Target to $338.00) (Mar. 11)
- Truist Securities: Buy (Lowers Target to $360.00) (Feb. 19)
Insulet Benzinga Edge Rankings
Below is the Benzinga Edge scorecard for Insulet, highlighting its strengths and weaknesses compared to the broader market:
- Value Rank: 24.2 — Trading at a steep premium relative to peers.
- Growth Rank: 88.97 — Strong growth potential indicated.
- Quality Rank: 53.27 — Balance sheet remains healthy.
- Momentum Rank: 13.17 — Stock is underperforming the broader market.
The Verdict: Insulet’s Benzinga Edge signal reveals a mixed outlook. While the Growth Rank indicates strong potential, the low Value and Momentum scores suggest that the stock may be overvalued and struggling to gain traction in the current market environment.
Insulet Top ETF Exposure
- Baron SMID Cap ETF (NYSE:BCSM): 2.36% Weight
- Main Thematic Innovation ETF (NASDAQ:TMAT): 1.83% Weight
- SPDR S&P Health Care Equipment ETF (NYSE:XHE): 2.03% Weight
PODD Price Action: Insulet shares were down 4.85% at $224.63 at the time of publication on Friday. The stock is trading at a new 52-week low, according to Benzinga Pro data.
Image via Insulet
Recent Comments